Insight Wealth Strategies LLC Buys 1,850 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Insight Wealth Strategies LLC boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 26.9% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 8,734 shares of the biopharmaceutical company’s stock after buying an additional 1,850 shares during the period. Insight Wealth Strategies LLC’s holdings in Regeneron Pharmaceuticals were worth $5,456,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of REGN. WPG Advisers LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 25 shares during the period. Western Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $26,000. SHP Wealth Management bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $26,000. Titan Wealth CI Ltd bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $29,000. Finally, Kemnay Advisory Services Inc. acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $31,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Trading Down 1.4%

Shares of REGN stock opened at $797.00 on Wednesday. The stock has a market cap of $82.06 billion, a P/E ratio of 19.70, a price-to-earnings-growth ratio of 1.37 and a beta of 0.22. Regeneron Pharmaceuticals, Inc. has a 1 year low of $541.00 and a 1 year high of $821.11. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The stock has a 50 day simple moving average of $665.31 and a 200 day simple moving average of $713.04.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The firm had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company’s revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the company earned $12.81 EPS. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is 9.29%.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 200 shares of the firm’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the company. Guggenheim upped their price objective on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Piper Sandler dropped their target price on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a report on Thursday, July 9th. JPMorgan Chase & Co. reduced their target price on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research report on Monday, May 18th. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a research note on Tuesday, July 7th. Finally, BMO Capital Markets decreased their price target on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a research note on Monday, May 18th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $797.75.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Goldman Sachs maintained its Buy rating on Regeneron, signaling continued confidence in the company’s business and pipeline prospects. Goldman Sachs Keeps Their Buy Rating on Regeneron
• Positive Sentiment: Recent analysis highlighted continued strength in Eylea HD and Dupixent, along with oncology growth and pipeline progress. The stock has risen 21.9% over the past month, although the sharp advance may also increase profit-taking risk. REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?
• Neutral Sentiment: The reported short-interest data shows zero shares sold short and a zero-day short-interest ratio, but the figures also contain an undefined percentage change and appear unreliable. Consequently, the data provides no meaningful indication of short-covering or bearish positioning.
• Negative Sentiment: Several law firms, including Pomerantz, Gross, Faruqi & Faruqi, and Hagens Berman, are promoting or reminding investors about a securities class action against Regeneron. The litigation follows disclosures that a Phase 3 melanoma therapy trial failed, an event reportedly associated with an approximately $11 billion market-capitalization loss. The legal notices themselves do not establish wrongdoing, but they add reputational and potential financial-risk concerns. Investors covered by the proposed class period may face a September 14, 2026 lead-plaintiff deadline. REGN Investor Alert

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.